Raymond Woosley earned a Ph.D. in Pharmacology from the University of Louisville and an M.D. from the University of Miami. Dr. Woosley specialized in Internal Medicine and Clinical Pharmacology at Vanderbilt University where he rose to the rank of Professor of Medicine. At Georgetown University he served as Chairman of the Department of Pharmacology and in 2000 was appointed Associate Dean for Clinical Research. In 2001 he became Vice President for Health Sciences at the University of Arizona and Dean of the College of Medicine. In January of 2005 he assumed the position as President of The Critical Path Institute (C-Path), a non-profit corporation formed by the Food and Drug Administration, SRI, International and the University of Arizona to accelerate the development of safe innovative medicines. Since 1999, he has directed one of seven federally funded Centers of Education and Research on Therapeutics (CERT). Dr. Woosley's research has been published in over 260 publications and has investigated the basic and clinical pharmacology of drugs for the drug treatment of arrhythmias and the cardiac toxicity of drugs. His research discovered the mechanism of the toxicity of the antihistamine Seldane that contributed to its subsequent removal from the market. For his contributions to medicine, he received the Rawls-Palmer Award from the American Society of Clinical Pharmacology and Therapeutics and the FDA Commissioner's Special Citation for his work to advise the agency on the toxicity of dietary supplements containing ephedra. In addition, Dr. Woosley is a Past-President of the Association for Medical School Pharmacology and the American Society for Clinical Pharmacology and Therapeutics. As a member of the University of Arizona's Sarver Heart Center and Bio5 Institute, he conducts research is on the prevention of adverse drug interactions.